pharmaphorum

Alnylam's ATTR cardiomyopathy drug backed for NHS use

Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...
Ecommerce Fastlane

What Is an Iframe? Pros, Cons, and How To Embed Them

Visitors to your website might want directions to your store via Google Maps, a roundup of your social media feeds, and a ...
findnerd.com

jQuery .prop() vs .attr()

Get the value of an attribute for the first element in the set of matched elements. An attribute value may only be a string. The attributes contains basic information ...
Health.com

4 Ways Doctors Can Detect ATTR-CM, a Rare and Difficult-To-Diagnose Heart Condition

Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...
PharmaTimes

NICE recommends vutrisiran for adults with ATTR-CM in final draft guidance

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending ...
Medscape

NICE Endorses Vutrisiran for ATTR-CM Treatment

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending vutrisiran for patients with wild-type and hereditary transthyretin amyloidosis with ...
Seeking Alpha

Intellia: Moving To 'Hold' Rating In Light Of Nex-Z Uncertainty In ATTR Patients (Downgrade)

The last time I spoke about Intellia Therapeutics (NTLA), it was with a Seeking Alpha article entitled "Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication" With respect to this ...
FiercePharma

Alnylam's Amvuttra blows past estimates again as ATTR-CM launch gains traction

Alnylam’s closely watched launch of its rare disease drug Amvuttra continued to outpace Wall Street expectations. Riding its March expansion into the heart condition of transthyretin amyloid ...
pharmaphorum

CRISPR biotech Intellia plummets as trial paused for safety

Gene-editing specialist Intellia Therapeutics lost more than 45% of its value in pre-market trading today as it revealed phase 3 trials of one of its two priority programmes had been suspended due to ...
Healthline

What to Know About Transthyretin Amyloidosis (ATTR) Genetic Testing

Genetic testing for ATTR can detect transthyretin mutations and offer crucial information about risk, monitoring, and treatment, if needed. Transthyretin amyloidosis (ATTR) is a genetic condition that ...
The New England Journal of Medicine

Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy

Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a rare, multisystem, progressive, debilitating, and fatal disease characterized by tissue deposition of misfolded transthyretin ...